Alumis (ALMS) Stock: Buy, Sell, or Hold?
ALMS - Alumis Inc. Common Stock
$6.82
0.01 (0.15%)
▲
5d:
+8.08%
30d:
-8.33%
90d:
-75.64%
BUY
HIGH Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 21, 2026 at $6.81 · last confirmed Oct 22, 2026
Strength: 7.5/10
Get Alerted When ALMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ALMS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ALMS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ALMS is currently trading at $6.82, which is considered slightly low relative to its 30-day fair value range of $6.50 to $8.07.
Technical Outlook: Technically, ALMS is in a strong downtrend. Immediate support is located at $6.01, while resistance sits at $7.31.
Market Sentiment: ALMS scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.12 (+357.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALMS is in a strong downtrend. Immediate support is located at $6.01, while resistance sits at $7.31.
Market Sentiment: ALMS scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $31.12 (+357.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$6.50 -
$8.07
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 357.0% below Wall St target ($31.12)
- BULLISH: Bottoming setup score 76/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$6.50 -
$8.07
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$6.01
Resistance Level
$7.31
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.37
Wall Street Target
$31.13
(+357.0%)
Revenue Growth (YoY)
-37.7%
Share & Embed Analysis
Last updated: October 22, 2026 4:41 PM ET
Data refreshes hourly during market hours. Next update: 5:41 PM
Data refreshes hourly during market hours. Next update: 5:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 61 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced ALMS Option Strategies
Professional options setups generated by AI based on today's ALMS price and gamma walls.
